The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.
  • Ticker

RNS




AstraZeneca PLC - AZN Trastuzumab deruxtecan granted FDA Priority Review
07:00 17-Oct-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Fasenra approved in the US for self-administration
07:00 04-Oct-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Director Declaration
16:00 03-Oct-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN AstraZeneca divests rights for Losec to Cheplaphar
07:05 01-Oct-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Update on US regulatory review of PT010 in COPD
07:00 01-Oct-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Lynparza more than doubled the time without
15:30 30-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Lynparza improved the time women lived without
07:00 30-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Tagrisso is the only 1st-line treatment for EGFR-
07:00 30-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Qtrilmet recommended for approval in EU by CHMP
07:00 23-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN AstraZeneca amends collaboration with Ironwood
07:00 18-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Imfinzi is first immunotherapy to show both
08:38 09-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Tagrisso approved in China as a 1st-line treatment
07:11 04-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Brilinta reduced the risk of cardiovascular events
07:05 02-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Detailed results from Phase III DAPA-HF trial
07:00 02-Sep-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Anifrolumab Phase III trial meets primary endpoint
07:00 29-Aug-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Fasenra granted US Orphan Drug Designation for
07:05 28-Aug-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Breztri Aerosphere Phase III ETHOS trial met
07:00 28-Aug-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Roxadustat approved in China for the treatment of
07:00 22-Aug-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN AstraZeneca agrees to buy US FDA Priority Review
07:00 22-Aug-2019  RNS  0.72% View chart
AstraZeneca PLC - AZN Update on the Phase III NEPTUNE trial
07:00 21-Aug-2019  RNS  0.72% View chart

 Page 1 of 2

| 1 | 2 | Next



RNS - regulatory news service - home


MARKET NEWS – SEARCH FEATURES

Market News is the definitive place to view real-time UK regulatory disclosures.

You will see a clear and comprehensive search, filter and sort features giving users the ability to:

  • Show only Earnings and News announcements - the default search
  • Show all announcements excluding NAVs & FRNs
  • Show all announcement types
  • See up to 500 stories per page
  • See ‘Most read news’ ticker at the top of the page
  • Select stories by Name/code, source, type, index or sector


about rns

 

News Sources

For information about RNS reach and News Announcements, the news sources available within the Market news section.



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds